[1]
|
Zhou, Z. and Hu, D. (2008) An Epidemiological Study on the Prevalence of Atrial Fibrillation in the Chinese Population of Mainland China. The Journal of Epidemiology, 18, 209-216. https://doi.org/10.2188/jea.JE2008021
|
[2]
|
Lin, H.J., Wolf, P.A., Kelly-Hayes, M., Beiser, A.S., Kase, C.S., Benjamin, E.J. and D’Agostino, R.B. (1996) Stroke Severity in Atrial Fibrillation. The Framingham Study. Stroke, 27, 1760-1764. https://doi.org/10.1161/01.STR.27.10.1760
|
[3]
|
Pitt, A., Ruff, C.T. and Giugliano, R.P. (2016) Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation. Hematology/Oncology Clinics of North America, 30, 1019-1034. https://doi.org/10.1016/j.hoc.2016.05.002
|
[4]
|
Go, A.S., Hylek, E.M., Borowsky, L.H., Phillips, K.A., Selby, J.V. and Singer, D.E. (1999) Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Annals of Internal Medicine, 131, 927-934.
https://doi.org/10.7326/0003-4819-131-12-199912210-00004
|
[5]
|
Connolly, S.J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M.G., Healey, J.S., Yusuf, S. and Investigators, A.W. (2008) Benefit of Oral Anticoagulant over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. Circulation, 118, 2029-2037.
https://doi.org/10.1161/CIRCULATIONAHA.107.750000
|
[6]
|
Gallagher, A.M., de Vries, F., Plumb, J.M., Hass, B., Clemens, A. and van Staa, T.P. (2012) Quality of INR Control and Outcomes Following Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 18, 370-378.
https://doi.org/10.1177/1076029611426139
|
[7]
|
Voora, D., McLeod, H.L., Eby, C. and Gage, B.F. (2005) The Pharmacogenetics of Coumarin Therapy. Pharmacogenomics, 6, 503-513.
https://doi.org/10.2217/14622416.6.5.503
|
[8]
|
Sconce, E.A., Khan, T.I., Wynne, H.A., Avery, P., Monkhouse, L., King, B.P., Wood, P., Kesteven, P., Daly, A.K. and Kamali, F. (2005) The Impact of CYP2C9 and VKORC1 Genetic Polymorphism and Patient Characteristics upon Warfarin Dose Requirements: Proposal for a New Dosing Regimen. Blood, 106, 2329-2333.
https://doi.org/10.1182/blood-2005-03-1108
|
[9]
|
Carlquist, J.F., Horne, B.D., Muhlestein, J.B., Lappe, D.L., Whiting, B.M., Kolek, M.J., Clarke, J.L., James, B.C. and Anderson, J.L. (2006) Genotypes of the Cytochrome p450 Isoform, CYP2C9, and the Vitamin K Epoxide Reductase Complex Subunit 1 Conjointly Determine Stable Warfarin Dose: A Prospective Study. Journal of Thrombosis and Thrombolysis, 22, 191-197.
https://doi.org/10.1007/s11239-006-9030-7
|
[10]
|
Rieder, M.J., Reiner, A.P., Gage, B.F., Nickerson, D.A., Eby, C.S., McLeod, H.L., Blough, D.K., Thummel, K.E., Veenstra, D.L. and Rettie, A.E. (2005) Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose. The New England Journal of Medicine, 352, 2285-2293.
https://doi.org/10.1056/NEJMoa044503
|
[11]
|
Jia, L., Wang, Z., Men, J., Cai, H. and Wei, M. (2017) Polymorphisms of VKORC1 and CYP2C9 Are Associated with Warfarin Sensitivity in Chinese Population. Therapeutics and Clinical Risk Management, 13, 421-425.
https://doi.org/10.2147/TCRM.S130198
|
[12]
|
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.C., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A.S., Oldgren, J., Popescu, B.A., Schotten, U., Putte, B.V., Vardas, P. and ESC Scientific Document Group (2016) ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS. European Heart Journal, 37, 2893-2962.
https://doi.org/10.1093/eurheartj/ehw210
|
[13]
|
Bando, S., Nishikado, A., Hiura, N., Ikeda, S., Kakutani, A., Yamamoto, K., Kaname, N., Fukatani, M., Takagi, Y., Yukiiri, K., Fukuda, Y. and Nakaya, Y. (2018) Efficacy and Safety of Rivaroxaban in Extreme Elderly Patients with Atrial Fibrillation: Analysis of the Shikoku Rivaroxaban Registry Trial (SRRT). Journal of Cardiology, 71, 197-201. https://doi.org/10.1016/j.jjcc.2017.08.005
|
[14]
|
D’Andrea, G., D’Ambrosio, R.L., Perna, P.D., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E. and Margaglione, M. (2005) A Polymorphism in the VKORC1 Gene Is Associated with an Interindividual Variability in the Dose-Anticoagulant Effect of Warfarin. Blood, 105, 645-649.
https://doi.org/10.1182/blood-2004-06-2111
|
[15]
|
Jofe, H.V., Xu, R.L., Johnson, F.B., Longtine, J., Kucher, N. and Goldhaber, S.Z. (2004) Warfarin Dosing and Cytochrome P450 2C9 Polymorphisms. Thrombosis and Haemostasis, 91, 1123-1128. https://doi.org/10.1160/TH04-02-0083
|
[16]
|
Park, Y.K., Lee, M.J., Kim, J.H., Lee, J.S., Park, R.W., Kim, G.M., Chung, C.S., Lee, K.H., Kim, J.S., Lee, S.Y. and Bang, O.Y. (2017) Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation. Journal of Stroke and Cerebrovascular Diseases, 26, 1383-1390.
https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.02.022
|
[17]
|
Chen, J., Shao, L., Gong, L., Luo, F., Wang, J., Shi, Y., Tan, Y., Chen, Q., Zhang, Y., Hui, R. and Wang, Y. (2014) A Pharmacogenetics-Based Warfarin Maintenance Dosing Algorithm from Northern Chinese Patients. PLoS ONE, 9, e105250.
https://doi.org/10.1371/journal.pone.0105250
|
[18]
|
Li, B., Liu, R., Wang, C., Ren, C., Zhang, S., Zhang, F., Zhang, J., Liu, S., Wei, Y., Liu, W., Song, B. and Wu, X. (2019) Impact of Genetic and Clinical Factors on Warfarin Therapy in Patients Early after Heart Valve Replacement Surgery. European Journal of Clinical Pharmacology, 75, 1685-1693.
https://doi.org/10.1007/s00228-019-02747-5
|
[19]
|
Hillman, M.A., Wilke, R.A., Caldwell, M.D., Berg, R.L., Glurich, I. and Burmester, J.K. (2004) Relative Impact of Covariates in Prescribing Warfarin According to CYP2C9 Genotype. Pharmacogenetics, 14, 539-547.
https://doi.org/10.1097/01.fpc.0000114760.08559.dc
|
[20]
|
Lenzini, P., Wadelius, M., Kimmel, S., Anderson, J.L., Jorgensen, A.L., Pirmohamed, M., Caldwell, M.D., Limdi, N., Burmester, J.K., Dowd, M.B., Angchaisuksiri, P., Bass, A.R., Chen, J., Eriksson, N., Rane, A., Lindh, J.D., Carlquist, J.F., Horne, B.D., Grice, G., Milligan, P.E., Eby, C., Shin, J., Kim, H., Kurnik, D., Stein, C.M., McMillin, G., Pendleton, R.C., Berg, R.L., Deloukas, P. and Gage, B.F. (2010) Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing. Clinical Pharmacology & Therapeutics, 87, 572-578. https://doi.org/10.1038/clpt.2010.13
|
[21]
|
Garcia, D., Regan, S., Crowther, M., Hughes, R.A. and Hylek, E.M. (2005) Warfarin Maintenance Dosing Patterns in Clinical Practice: Implications for Safer Anticoagulation in the Elderly Population. Chest, 127, 2049-2056.
https://doi.org/10.1378/chest.127.6.2049
|